5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 10.03▲ | 10.03▲ | 10.03▲ | 10.05▲ | 10.04▲ |
MA10 | 10.01▲ | 10.01▲ | 10.01▲ | 10.04▲ | 10.04▲ |
MA20 | N/A | N/A | N/A | 10.05▲ | N/A |
MA50 | N/A | N/A | N/A | 10.03▲ | N/A |
MA100 | N/A | N/A | N/A | N/A | N/A |
MA200 | N/A | N/A | N/A | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | N/A | N/A | N/A | 0.000▲ | N/A |
RSI | 76.833▲ | 76.589▲ | 75.862▲ | 61.736▲ | N/A |
STOCH | 80.000▲ | N/A | N/A | 11.726▼ | N/A |
WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -66.556 | -28.592 |
CCI | 212.121▲ | 212.095▲ | 204.359▲ | 123.905▲ | 135.585▲ |
Saturday, October 11, 2025 09:13 PM
Teva Pharmaceutical Industries (NYSE:TEVA) just landed U.S. FDA approval for UZEDY, an extended-release injectable developed with Medincell, for adults living with bipolar I disorder. This move ...
|
Wednesday, October 01, 2025 05:38 PM
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the 20 NYSE Stocks with the Lowest P/E Ratios. UBS maintained its Buy rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA) on ...
|
Wednesday, October 01, 2025 05:27 PM
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the 12 Best Widow and Orphan Stocks to Buy According to Analysts. On September 23, 2025, Truist Securities reaffirmed its Buy rating for Teva ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
10/10/25 | 10.06 | 10.06 | 10.06 | 10.06 | 0 |
09/10/25 | 10.05 | 10.10 | 10.05 | 10.06 | 62,200 |
08/10/25 | 10.04 | 10.045 | 10.04 | 10.04 | 59,000 |
07/10/25 | 10.04 | 10.04 | 10.04 | 10.04 | 0 |
06/10/25 | 10.04 | 10.04 | 10.04 | 10.04 | 0 |
03/10/25 | 10.04 | 10.04 | 10.04 | 10.04 | 416,300 |
02/10/25 | 10.04 | 10.04 | 10.04 | 10.04 | 25,900 |
01/10/25 | 10.0399 | 10.05 | 10.0399 | 10.05 | 12,373 |
30/09/25 | 10.04 | 10.04 | 10.04 | 10.04 | 0 |
29/09/25 | 10.04 | 10.04 | 10.04 | 10.04 | 0 |
|
|
||||
|
|
||||
|
|